Deliverable
No¹

Deliverable title

Delivery
date²

Nature³

Dissemination
level⁴

D1.1

Report breeding of mouse models (NZO (New Zealand Obese), SJL (Swiss Jim Lambert), and C57BL/6 laboratory mice) with phenotyping of mouse models and recording of essential physiological parameters (weight, fat mass, blood glucose, insulin

18

R

PU

D1.2

Generation of samples and developing and establishing standard protocols for sample preparation and processing. Tissues and samples generated for proteome analysis: blood, white fat, liver muscle.

12

R

PP

D1.3

Developing and characterizing engineered cell models for functional validation of relevant target genes

24

O, R

PP

D1.4

Validation of relevant target genes: serum amyloid protein (SAA), chemokine (C-C motiv), complement component factor B, cathepsin D

36

R, O

RE

D2.1

SOP for sample generation

12

R

RE

D2.2

Protocol for the optimisation of DIGE and phosphopeptide/protein enrichment for mouse tissue samples

18

R, O

PU

D2.3

Identification and characterisation of differentially expressed proteins based on a minimum of 100 complex protein mixture mass spectrometry runs

18

R

RE

D2.4

Q Quantitative proteome profiles using quantitative labels on a minimum of 1000 different proteins

18

R

RE

D2.5

Identification and mapping of phosphorylation state and putative post-translational modifications of differentially expressed isoforms and proteins, generation of up-to 100.000 mass spectra

36

R

RE

D2.6

Transfer optimisation and profiling of existing serum analysis protocols for small-quantity mouse serum

24

R, O

PU

D2.7

Identification and characterisation of serum biomarkers

36

R, O

CO

D3.1

Specification of requirements for the analysis of high-throughput PTM data and the detection of serum marker, generation of a requirement specification

6

R

RE

D3.2

Test data set for development and testing of new algorithms and for methods for serum analysis

6

R, O

PU

D3.3

Prototype of PTM-discovery tool

18

R, O

RE

D3.4

Prototype of serum profiling tool

18

R, O

RE

D3.5

List of detected PTMs and stable markers from serum

36

R, O

CO

D4.1

Modelling platforms available (Petri net and differential equation based) and interfaces for data import established

12

O, R

PU

D4.2

Correlation analysis report – mapping of physiological parameters (weight, fat mass, blood glucose, insulin) to molecular pathways (mTOR signalling pathway, insulin signalling pathway adipocytokine signalling pathway type II diabetes mellitus citrate cycle (TCA cycle) Glycolysis/Gluconeogenesis, fatty acid metabolism, toll-like receptor signalling pathway)

18

R

PU

D4.3

Report on effect of physiological parameters (weight, fat mass, blood glucose, insulin) on physiological disease model (glucose flux, insulin, fat mass, hormones(adiponectin, glucagon; RBP4, adipocytcines), cytocines, chemokines)

36

O, R

RE

D4.4

Hybrid model combining molecular level with the physiological level on different phenotypic conditions (hyerglycemia and hyperinsulinaemia (insulin resistance), hyperglycemia and hypoinsulinemia (overt diabetes), implementation and refinement

36

O,R

RE

D5.1

Knowledge base prototype

12

R, O

RE

D5.2

Import interfaces and quality control routines

18

R, O

RE

D5.3

Prototype of disease model

18

R, O

RE

D5.4

Validated disease model

36

R, O

RE

D6.1

Consortium agreement signed

2

R

CO

D6.2

Report about the recruitment progress

6

R

CO

D6.3

Financial reports (x2)

18/36

R

CO

D6.4

Management reports (x2)

18/36

R

CO

D6.5

Content reports (x2)

18/36

R

CO